FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,090 | -89.2% | 984 | -75.7% | 0.00% | – |
| Q2 2023 | $19,297 | +5.8% | 4,054 | +26.7% | 0.00% | – |
| Q1 2023 | $18,234 | -20.8% | 3,199 | +40.2% | 0.00% | -100.0% |
| Q4 2022 | $23,015 | -11.5% | 2,281 | +98.2% | 0.00% | 0.0% |
| Q3 2022 | $26,000 | -3.7% | 1,151 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $27,000 | -20.6% | 1,070 | +22.8% | 0.00% | 0.0% |
| Q1 2022 | $34,000 | 0.0% | 871 | +48.1% | 0.00% | 0.0% |
| Q4 2021 | $34,000 | -35.8% | 588 | -34.7% | 0.00% | -50.0% |
| Q3 2021 | $53,000 | -32.9% | 901 | -0.7% | 0.00% | -33.3% |
| Q2 2021 | $79,000 | +393.8% | 907 | +372.4% | 0.00% | +200.0% |
| Q1 2021 | $16,000 | -5.9% | 192 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $17,000 | +112.5% | 192 | -5.4% | 0.00% | – |
| Q3 2020 | $8,000 | +60.0% | 203 | +31.0% | 0.00% | – |
| Q2 2020 | $5,000 | +66.7% | 155 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | – | 155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |